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ABSTRACT
Objective: The present study gives a simple, rapid, and accurate stability indicating reverse phase high-performance liquid chromatography method 
for the determination of loxapine succinate and its related substance (related compound A) in capsule dosage form.
Methods: Loxapine succinate and its related substance were attained on a C18 Purospher star (250 mm × 4.6 mm, 5 µm particle size) column at 
254 nm detection wavelength, 1.0 ml/min as a flow rate, and 10 µl injection volume. Water:methanol: Triethylamine: Tetrahydrofuran (50:40:1:10) 
was used a mobile phase, and column oven temperature was 30°C.
Results: The resolution between loxapine succinate and known unknown impurities was >2.0. The correlation coefficient (0.999) value indicates 
the linear relationship between the concentration and peak areas. The accuracy study was performed by spiking method. Loxapine succinate was 
exposed to the stress condition of hydrolysis (acid and base), oxidative, thermal, and photolytic degradation. Loxapine succinate was found to degrade 
unquestionably in acid and base stress condition and almost stable in oxidative, thermal, and photolytic conditions.
Conclusion: The degradant products were well resolved from leading peak and its related compound A peak and any other unknown peak justifying 
the stability indicating capability of the method. The developed method was validated as per the ICH guidelines. This method is used for periodic 
analysis in laboratory.
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INTRODUCTION
Loxapine succinate is a typical antipsychotic drug, member of 
dibenzoxazepine class and used to cure certain cerebral or mood 
disorders (such as schizophrenia). Loxapine succinate is a dopamine 
antagonist and also serotonin 5-hydroxytryptamine 2 blockers. The 
specific mode of action of loxapine succinate has not established. 
This drug helps in compressing assault and illusion [1-3]. Loxapine is 
present in capsules as a succinate salt.
Its IUPAC name is 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]
benzoxazepine. Its molecular weight is 445.9 g/mole.
Chemical structure of loxapine succinate is shown in Fig. 1 [4-7].
Impurities will be quantified as known impurity: Loxapine related 
compound A. Chemical structure of loxapine succinate is shown in Fig. 2.
All other peaks will be considered as unknown impurities [8].
Literature search admits that several methods were reported, namely 
ultraviolet (UV) method, high-performance liquid chromatography 
(HPLC) method, HPLC-tandem mass spectrometry, and gas 
chromatography–mass spectrometry method. However, there was 
no method reported for related substance. To successfully launch the 
product and to maintain market revenue, it should meet the therapeutic 
requirements along with safety for patients who will receive the 
medicine. For that purpose, we have to analyze the product and for 
which analytical method is needed. The rationale of the research is 
that loxapine succinate contains the degradant impurity, and our goal 
is to separate the degradant impurity with the main peak of loxapine 
succinate and it should not interfere with any other peak. Hence, there 
is a demand for developing related substance method for loxapine 
succinate in capsule dosage form. Hence, the authors made an endeavor 
to develop simple, accurate, sensitive, selective, and specific-related 




Loxapine succinate was granted as a gift sample by Hetero drugs Ltd, 
Hyderabad, Andhra Pradesh, India. Capsule dosage form was bought up 
from local pharmacy. All the chemicals and reagents such as methanol, 
acetonitrile, and water were of HPLC grade and were procured from 
Merck Specialties Pvt. Ltd., Mumbai, India.
Instrumentation
HPLC waters Alliance 2695 series equipped with autosampler, 
temperature control, and autoinjector with capacity to inject 
5 µl–500 µl with PDA detector. Waters HPLC system is equipped with 
Empower 2 software finally optimized chromatographic condition is 
shown in Table 1.
Methods
Preparation of diluted standard solution
Accurately weighed and transferred 60 mg of loxapine succinate 
standard into 200 ml volumetric flask. Add diluents about 70% of 
flask volume and sonicate to dissolve the solution. Volume was made 
up to mark with diluents. Pipette out 5 ml of stock solution into 50 ml 
volumetric flask and volume made up to mark with diluents. Again 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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pipette out 5 ml of stock solution into 50 ml volumetric flask and 
volume made up to mark with diluents (3 µg/ml). Chromatogram of 
diluted standard (3 µg/ml) is shown in Fig. 3. Characterization of peak 
of diluted standard is shown in Table 2.
Related compound A stock
Accurately weighed and transferred 3 mg of related compound A into 
20 ml volumetric flask. Add 5 ml of diluents and sonicate to dissolve the 
solution and volume made up to mark with diluents.
Spiked sample (Loxapine 1500 µg/ml, ImpA 3 µg/ml)
Accurately weighed and transferred loxapine succinate equivalent 
to 75 mg of loxapine into 50 ml volumetric flask. Add 1 ml of related 
compound A stock solution. Add diluent about 50% of flask volume. 
Sonicate for 30 min with intermittent shaking, volume made up to 
mark with diluent. Solution filter using 0.45 µm Polyvinylidene fluoride 
filter after 5 ml of filtrate discarded. Chromatogram of Spiked sample is 
shown in Fig. 4. Characterization of peak of sample spiked with known 
impurity  is shown in Table 3.
RESULTS AND DISCUSSION
Validation of the method
The described method has been validated for the loxapine succinate and 
related compound A by HPLC determination as per the ICH guidelines.
Specificity and mass balance study
All forced degradation samples were analyzed at an initial 
concentration of 1500 µg/ml of loxapine succinate to ensure the 
homogeneity and purity of peak. The forced condition used for 
degradation studies was acid degradation (10 ml 1 N HCl, RT for 
5 h), base degradation (10 ml 0.1 N NaOH, RT for 5 h), oxidation 
(10 ml 30% H2O2, RT for 5 h), thermal (85°C for 7 days), and 
photolytic degradation (1.2 million lux hours of UV light 200 watt 
h/m2 for 7 days). Very significant degradation of loxapine succinate 
was observed in acidic and basic stress condition leading to the 
Fig. 7: Peroxide degradation sample chromatogram
Fig. 5: Acid degradation sample chromatogram
Fig. 1: Chemical structure of loxapine succinate
Fig. 2: Chemical structure of loxapine related compound A 
Fig. 3: Chromatogram of diluted standard (3 µg/ml)
Fig. 4: Chromatogram of spiked sample
Fig. 6: Base degradation sample chromatogram
Fig. 8: Thermal degradation sample chromatogram
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formation of loxapine related compound A. Significant degradation 
was observed in oxidative, thermal, and photolytic stress conditions. 
Chromatograms of sample degradation are shown in Figs. 5-9. Mass 
balance result was calculated for all stressed samples and found to 
between 95% and 102%. The purity angle was within the purity 
threshold limit obtained in all the stressed samples and gives the 
analyte peak homogeneity. Results of mass balance calculation are 
presented in Table 4.
Linearity and range
A series of solutions of loxapine related compound A ranging from 
limit of quantitation (LOQ) to 150% of specification level were 
prepared and injected into HPLC system. The linearity of the method 
was established by the plotting a graph between the concentration 
and response of loxapine related compound A. The results of the 
linearity study are presented in Table 5. It shows that the r2 is more 
than 0.990. The relative response factor (RRF) is used to control 
impurities in drug substance and drug product. It used to correct 
the differences in detector response of impurities with analyte peak. 
RRF is established by slope method with linear range of solution and 
found to be 2.685. Calibration curve of loxapine succinate is shown 
in Fig. 10.
Accuracy
Accuracy of an analytical procedure expresses the closeness 
of agreement between the true value and the value found. The 
accuracy of the method is established in terms of recovery. Sample 
solution for accuracy study was prepared in triplicate by spiking 
the impurities at the specification level (not more than 0.2% of 
each impurity) to the test sample at LOQ, 50%, 100%, and 150% 
of the specification level and injected into the HPLC system. 
Individual recovery, mean recovery, and percentage relative 
standard deviation (% RSD) at each level are presented in Table 6. 
Recoveries were found to be within the range of 90%–110% and 
meet with the ICH guidelines.
Precision
To evaluate the method precision for related substance, six replicates 
of test preparations (n = 6) of loxapine succinate were prepared and 
spiked known impurity at specification level and analyzed as per 
method. Percentage impurity calculated and reported in Table 7. % 
RSD values were found within the limits. The intermediate precision 
of the method was evaluated by adopting the same method using 
Fig. 9: Photolytic degradation sample chromatogram
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Fig. 10: Calibration curve of Loxapine succinate
Table 4: Forced degradation study‑percentage impurity with mass balance (drug product)
Sample name Purity angle Purity threshold Total impurities (%) Percentage assay Mass balance (%)
Control 1.974 2.198 0.0 99.5 NA
Acidic 2.045 2.185 10.25 90.95 101.70
Basic 1.875 2.095 10.16 92.83 103.50
Peroxide 1.836 1.946 0.0 94.81 95.28
Thermal 2.010 2.184 0.0 98.36 98.85
Photolytic 2.326 2.651 0.0 97.96 98.45
NA: Not available
Table 2: Characterization of peak of diluted standard
Peak name RT (min) Area (%) Tailing factor Purity angle Purity threshold
Loxapine succinate 26.541 50,135 (100) 1.5 0.781 1.421
RT: Retention time
Table 1: Optimized chromatographic conditions
Parameter Recommendation 
Column C18 Purospher star (250 mm×4.6 mm), 5 µm 
particle size
Column temperature 30°C
Mobile phase Water: methanol: TEA: THF: 50:40:1:10 ml
Flow rate 1.0 mL/min
Injection volume 10 µL
Detection wavelength 254 nm
Sampler temperature Ambient
Diluent Mobile phase
TEA: Triethylamine, THF: Tetrahydrofuran
Table 3: Characterization of peak of sample spiked with known impurity
Peak name RT (min) Area (%) Tailing factor USP resolution Purity angle Purity threshold
Loxapine succinate 26.654 24,670,304 (99.52) 1.7 - 1.974 2.198
Loxapine related compound A (impurity) 31.099 119,782 (0.48) 1.0 3.9 1.294 1.329
RT: Retention time, USP: United states pharmacopeia, A: Impurity
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Table 6: Accuracy results
Related Compound A
Level Concentration Area Percentage recovery Mean
LOQ 0.75 12,085 99.1 100.1
12,219 100.2
12,309 101.0
50% 1.5 59,134 98.57 99.3
59,321 98.89
60,266 100.46
100% 3.0 121,876 100.83 100.9
121,331 100.38
122,819 101.61
150% 4.5 180,875 99.07 99.3
181,129 99.21
182,088 99.74
LOQ: Limit of quantitation
Table 7: Method precision results
Precision set Spiked concentration Loxapine Related Compound A
Area Percentage impurity Area Percentage impurity
1 3 51,476 0.21 124,084 0.21
2 3 52,341 0.21 122,765 0.20
3 3 49,231 0.20 120,334 0.20
4 3 48,976 0.20 122,367 0.20
5 3 51,324 0.21 121,432 0.20
6 3 51,768 0.21 120,036 0.20
Average 0.20 0.20
SD 0.01 0.00
% RSD 2.8 1.3
SD: Standard deviation, % RSD: Percentage relative standard deviation
Table 8: Intermediate precision results
Precision set Spiked concentration Loxapine Related Compound A
Area Percentage impurity Area Percentage impurity
1 3 51,486 0.22 124,084 0.22
2 3 51,674 0.21 122,765 0.20
3 3 50,364 0.22 120,334 0.22
4 3 49,683 0.21 122,367 0.21
5 3 51,987 0.20 121,432 0.20
6 3 52,566 0.20 120,036 0.22
Average 0.21 0.21
SD 0.008 0.009
% RSD 4.2 4.6
SD: Standard deviation, % RSD: Percentage relative standard deviation
Table 9: Limit of detection limit of quantitation confirmation
Name LOD concentration (µg/ml) S/N ratio LOQ concentration (µg/ml) S/N ratio
Loxapine Related Compound A 0.225 4 0.75 12
LOQ: Limit of quantitation, LOD: Limit of detection, S/N: Signal to noise
different column, different HPLC system, and different days and 
results are enlisted in Table 8. % RSD values were found to be within 
the limits.
Limit of detection (LOD) and LOQ
LOD and LOQ for related substance are determined by injecting a series 
of solution of known concentration till the signal-to-noise ratio became 
as 3:1 and 10:1, respectively, and results are summarized in Table 9. The 
LOD and LOQ values were determined as 0.225 µg/ml and 0.75 µg/ml 
for loxapine related compound A.
Robustness
The robustness of method was studied by injecting the blank and 
standard with willfully changes in flow rate of mobile phase, change 
in wavelength, and change in column temperature. The results of the 
robustness are given in Table 10. Results showed that method is not 
affected by intentionally changes in method parameters which was 
proved by % RSD of three replicates of standards <2.
CONCLUSION
A specific, precise, linear, and accurate stability indicating HPLC method 
has been developed for the quantification of loxapine succinate related 
compound A. The method has been validated for specificity, stability, 
linearity, range, accuracy, precision, and robustness. This method is 
able to quantify all known impurities in the presence of other unknown 
impurities within specification limit. As the method is validated in 
accordance with ICH Q2(R1) guideline, it could be taken up for the 
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Table 10: Robustness results
S.No. Robustness parameter Loxapine succinate
% RSD Tailing factor Theoretical plates
1 Low flow (0.8 ml/min) 1.1 1.4 12,553
2 High flow (1.2 ml/min) 1.5 1.2 13,764
3 Low wavelength (252 nm) 1.2 1.5 12,344
4 High wavelength (256 nm) 1.0 1.0 13,879
5 Low column temperature (28°C) 1.4 1.2 12,984
6 High column temperature (32°C) 0.9 1.3 23,786
% RSD: Percentage relative standard deviation
analysis of related substance in the dosage form of loxapine succinate 
in pharmaceutical industries.
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